Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NYM096
- Development stage
- Phase 1
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
68Ga-NYM096 is a radiopharmaceutical diagnostic agent developed for positron emission tomography (PET) imaging. It consists of a small-molecule ligand, NYM096, which is a potent inhibitor of Fibroblast Activation Protein (FAP), conjugated to the radioisotope Gallium-68 (68Ga) via a DOTA chelator. FAP is a type II transmembrane serine protease that is significantly overexpressed on cancer-associated fibroblasts (CAFs) within the stroma of various epithelial tumors, including lung, pancreatic, and breast cancers, while remaining nearly undetectable in most healthy adult tissues. By targeting the tumor microenvironment rather than the tumor cells themselves, 68Ga-NYM096 provides high-contrast imaging with low background activity. It is primarily investigated for its utility in tumor staging, detection of metastases, and monitoring treatment response, often demonstrating superior sensitivity to 18F-FDG in specific malignancies such as gastric and hepatic cancers.
- Other names
- Gallium-68 NYM096Gallium68 NYM096Gallium 68 NYM096[68Ga]Ga-NYM09668Ga-DOTA-NYM096
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 68Ga-NYM096.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NYM096.